AKEBIA THERAPEUTICS, INC. Financing Cash Flow
AKEBIA THERAPEUTICS, INC. (AKBA) reported Financing Cash Flow of -$7.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$6.54M, a 480.12% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$926.00K, a 101.24% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$4.85M, a 121.72% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.11M, a 8.99% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $72.93M, a 46.84% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $49.66M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was -$25.21M, a 272.67% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $14.60M, a 89.08% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$7.46M 10-Q · filed 2026-08-05 | -$12.31M derived: sum of 3 quarters · filed 2026-08-05 | -$11.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$926.00K 10-Q · filed 2026-05-07 | -$5.77M derived: sum of 2 quarters · filed 2026-05-07 | -$4.66M derived: sum of 3 quarters · filed 2026-05-07 | -$2.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.73M derived: sum of 2 quarters · filed 2026-02-26 | -$2.02M derived: sum of 3 quarters · filed 2026-08-05 | $72.93M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.83M derived: sum of 2 quarters · filed 2026-08-05 | $77.78M 10-Q · filed 2025-11-10 | $100.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $76.66M 10-Q · filed 2026-08-05 | $98.99M derived: sum of 3 quarters · filed 2026-08-05 | $100.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $74.94M 10-Q · filed 2026-05-07 | $97.27M derived: sum of 2 quarters · filed 2026-05-07 | $98.49M derived: sum of 3 quarters · filed 2026-05-07 | $106.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $22.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.55M derived: sum of 2 quarters · filed 2026-02-26 | $31.19M derived: sum of 3 quarters · filed 2026-02-26 | $49.66M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $8.86M derived: sum of 2 quarters · filed 2025-11-10 | $27.34M 10-Q · filed 2025-11-10 | $26.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $7.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $26.11M 10-Q · filed 2025-08-07 | $24.82M derived: sum of 3 quarters · filed 2026-02-26 | $24.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $18.48M 10-Q · filed 2025-05-08 | $17.18M derived: sum of 2 quarters · filed 2026-02-26 | $17.23M derived: sum of 3 quarters · filed 2026-02-26 | $9.23M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.24M derived: sum of 2 quarters · filed 2026-02-26 | -$9.24M derived: sum of 3 quarters · filed 2026-02-26 | -$25.21M 10-K · filed 2026-02-26 |
| 2023-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$7.95M derived: sum of 2 quarters · filed 2024-11-07 | -$23.92M 10-Q · filed 2024-11-07 | -$23.92M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$23.97M 10-Q · filed 2024-08-08 | -$23.97M derived: sum of 3 quarters · filed 2024-08-08 | -$56.90M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$15.97M 10-Q · filed 2024-05-09 | -$15.97M derived: sum of 2 quarters · filed 2024-05-09 | -$48.90M derived: sum of 3 quarters · filed 2024-05-09 | -$48.91M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$32.94M derived: sum of 2 quarters · filed 2024-03-14 | -$32.95M derived: sum of 3 quarters · filed 2024-03-14 | $14.60M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$32.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$32.95M derived: sum of 2 quarters · filed 2023-11-08 | $14.60M 10-Q · filed 2023-11-08 | $20.00M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-28 | $47.54M 10-Q · filed 2023-08-28 | $52.94M derived: sum of 3 quarters · filed 2023-08-28 | $69.42M derived: sum of 4 quarters · filed 2023-08-28 |
| 2022-03-31 | $47.55M 10-Q · filed 2023-05-08 | $52.95M derived: sum of 2 quarters · filed 2023-08-28 | $69.43M derived: sum of 3 quarters · filed 2023-08-28 | $106.80M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-12-31 | $5.40M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $21.89M derived: sum of 2 quarters · filed 2023-08-28 | $59.25M derived: sum of 3 quarters · filed 2023-08-28 | $133.73M 10-K/A · filed 2023-08-28 |
| 2021-09-30 | $16.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $53.85M derived: sum of 2 quarters · filed 2022-11-03 | $128.33M 10-Q · filed 2022-11-03 | $158.84M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-06-30 | $37.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $111.85M 10-Q · filed 2022-08-04 | $142.36M derived: sum of 3 quarters · filed 2023-08-28 | $143.41M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-03-31 | $74.48M 10-Q · filed 2022-05-09 | $104.99M derived: sum of 2 quarters · filed 2023-08-28 | $106.04M derived: sum of 3 quarters · filed 2023-08-28 | $248.85M derived: sum of 4 quarters · filed 2023-08-28 |
| 2020-12-31 | $30.51M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $31.57M derived: sum of 2 quarters · filed 2023-08-28 | $174.37M derived: sum of 3 quarters · filed 2023-08-28 | $231.72M 10-K/A · filed 2023-08-28 |
| 2020-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $143.86M derived: sum of 2 quarters · filed 2021-11-04 | $201.21M 10-Q · filed 2021-11-04 | $295.63M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $142.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $200.16M 10-Q · filed 2021-08-05 | $294.57M derived: sum of 3 quarters · filed 2022-03-01 | $294.77M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $57.35M 10-Q · filed 2021-05-10 | $151.77M derived: sum of 2 quarters · filed 2022-03-01 | $151.96M derived: sum of 3 quarters · filed 2022-03-01 | $160.76M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $94.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $94.61M derived: sum of 2 quarters · filed 2022-03-01 | $103.42M derived: sum of 3 quarters · filed 2022-03-01 | $88.97M 10-K · filed 2022-03-01 |
| 2019-09-30 | $195.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $9.00M derived: sum of 2 quarters · filed 2020-11-05 | -$5.45M 10-Q · filed 2020-11-05 | -$5.36M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $8.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$5.64M 10-Q · filed 2020-08-10 | -$5.56M derived: sum of 3 quarters · filed 2021-02-25 | -$5.20M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$14.45M 10-Q · filed 2020-05-05 | -$14.36M derived: sum of 2 quarters · filed 2021-02-25 | -$14.01M derived: sum of 3 quarters · filed 2021-02-25 | -$13.80M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $439.00K derived: sum of 2 quarters · filed 2021-02-25 | $651.00K derived: sum of 3 quarters · filed 2021-02-25 | $96.56M 10-K · filed 2021-02-25 |
| 2018-09-30 | $354.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $566.00K derived: sum of 2 quarters · filed 2019-11-12 | $96.48M 10-Q · filed 2019-11-12 | $101.72M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $212.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $96.12M 10-Q · filed 2019-08-08 | $101.37M derived: sum of 3 quarters · filed 2020-03-12 | $165.15M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $95.91M 10-Q · filed 2019-05-09 | $101.15M derived: sum of 2 quarters · filed 2020-03-12 | $164.94M derived: sum of 3 quarters · filed 2020-03-12 | |
| 2017-12-31 | $5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $69.03M derived: sum of 2 quarters · filed 2020-03-12 | $116.24M 10-K · filed 2020-03-12 | |
| 2017-09-30 | $63.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $111.00M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $47.21M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | $66.95M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |